세계 급성 림프구성 백혈병 치료제 시장 : 세포 유형별, 치료 유형별 10개국 이상의 데이터 분석 및 예측(2024년-2033년)

Global Acute Lymphoblastic Leukemia Therapeutics Market: Focus on Cell Type, Therapy Type, and Over 10 Countries´ Data - Analysis and Forecast, 2024-2033

US $ 2,475 ￦ 3,440,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 3,825 ￦ 5,317,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

급성 림프구성 백혈병(ALL)은 급성 림프성 백혈병으로도 알려져 있으며, 골수와 혈액을 괴롭히는 악성 질환입니다.

초기 림프구 전구 세포가 과도하게 성장하고 골수에서 정상 조혈 세포가 대체되는 것이 특징입니다. ALL은 미국 소아에서 암과 백혈병에서 가장 흔한 유형입니다.

세계 급성 림프구성 백혈병(ALL) 시장은 증례 수 증가와 함께 역동적인 양상을 보이고 있습니다. 다양한 이유가 확인되었지만, 앉아있는 라이프 스타일과 건강에 해로운 식습관이이 질병과보다 일반적으로 관련되어 있습니다. 또한, 예방의료 및 진단에 대한 의식이 높아짐에 따라 유병률은 향후 수년간 증가할 것으로 추정됩니다.

현재의 급성 림프구성 백혈병 시장은 중견기업 외에도 대기업도 참가하고 있어 경쟁은 완만합니다. 많은 제약 기업이 암 영역에 중점을 두게 되어 있기 때문에 동 시장에서는 당분간, 소규모 기업의 신규 참가가 예상됩니다.

본 보고서는 세계 급성 림프구성 백혈병 치료제 시장에 대해 조사했으며,, 시장 개요와 함께 세포 유형별, 치료 유형별, 지역별 동향, 시장 진출기업 프로파일 등을 제공합니다.

목차

주요 요약

범위 및 정의

제1장 시장

• 동향 : 현재 및 미래의 영향 평가
• 공급망 개요
• 연구개발 리뷰
• 임상시험의 정세
• 규제 상황
• 이해관계자 분석
• 주요 세계적 사건의 영향 분석-COVID-19
• 시장 역학 개요
• 상환 시나리오

제2장 용도

• 용도의 세분화
• 용도 개요
• 세계 급성 림프구성 백혈병 치료제 시장(세포 유형별)

제3장 제품

• 제품의 세분화
• 제품 개요
• 세계 급성 림프구성 백혈병 치료제 시장(제품 및 서비스별)

제4장 지역

• 지역별 개요
• 성장 촉진요인과 억제요인
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제5장 시장 - 경쟁 벤치마킹 및 기업 프로파일

• 미래 유망 기업
• 지리적 평가
  • AbbVie Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Erytech Pharma Inc.
  • Fate Therapeutics
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GSK plc.
  • Jazz Pharmaceuticals, Inc.
  • Juventas Cell Therapy Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Seagen Inc.
  • Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

제6장 조사 방법

JHS

영문 목차

영문목차

“Global Acute Lymphoblastic Leukemia Therapeutics Market Shows Promising Growth Prospects.”

Acute lymphoblastic leukemia (ALL), also known as Acute Lymphocytic Leukemia or Acute Lymphoid Leukemia, is a malignant disease affecting the bone marrow and blood. It is characterized by the excessive proliferation of early lymphoid precursors, leading to the displacement of normal hematopoietic cells in the marrow. ALL is the most prevalent type of cancer and leukemia among children in the U.S.

The global market for Acute Lymphoblastic Leukemia (ALL) is witnessing a dynamic landscape with growing number of cases. Among the various reasons identified, sedentary lifestyle and unhealthy eating habits are more commonly associated with the disease. Furthermore, prevalence is estimated to increases in coming years owing to increased awareness about preventive care and diagnostics.

The current acute lymphoblastic leukemia market demonstrates moderate competitiveness, featuring established major players alongside mid-sized companies. Given the increasing emphasis of numerous pharmaceutical companies on oncology, the market is expected to witness entry of new small-sized companies in the foreseeable future.

• This report aims to provide a comprehensive analysis of the ALL market, focusing on current unmet needs, trends, challenges and opportunities shaping the industry landscape.
• This report provides an in-depth analysis of pipeline landscape of the ALL market along with growth based on different market segments.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the ALL Market.
• This report presents a sound forecast estimates of the ALL market to help investors as well as industry players in taking informed decisions.

Market Segmentation:

Segmentation 1: by Cell Type

• B-cell ALL
• T-cell ALL
• Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL

Segmentation 2: by Therapy Type

• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Stem Cell Transplantation

Segmentation 3: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

Key Questions Answered in the Report:

• What is the present size of the global acute lymphoblastic leukemia therapeutics (ALL) market?
• Who are the major contributors in the global ALL therapeutics market?
• Which region is experiencing the most rapid growth in the global ALL therapeutics market?
• Which geographical area holds the largest portion of the global ALL therapeutics market?
• What is the projected Compound Annual Growth Rate (CAGR) for the ALL therapeutics market?
• What are the primary factors propelling growth in the ALL therapeutics market?
• What are critical factors posing challenge to the growth of global ALL therapeutics market?
• Which sector is predicted to spearhead the global ALL therapeutics market by 2033?

Table of Contents

Executive Summary

Scope and Definition

1. Markets

• 1.1. Trends: Current and Future Impact Assessment
  • 1.1.1. Sample Text
  • 1.1.2. Trend 1- Increased Number of ALL Cases
  • 1.1.3. Trend 2- Focus on Addressing Treatment Induced Side-effects
  • 1.1.4. Trend 3- Focus on Preventive Care
• 1.2. Supply chain Overview
  • 1.2.1. Value Chain Analysis
  • 1.2.2. Market Map
  • 1.2.3. Pricing Forecast for Raw Materials and Components
• 1.3. Research and Development Review
  • 1.3.1. Patent Filing Trend (by Country, Company)
• 1.4. Clinical Trial Landscape
  • 1.4.1. Clinical Landscape (by Development Stage)
  • 1.4.2. Clinical Landscape (by Drug Class)
• 1.5. Regulatory Landscape
• 1.6. Stakeholder Analysis
  • 1.6.1. Use case
  • 1.6.2. End User and Buying Criteria
• 1.7. Impact Analysis for Key Global Events- Covid19
• 1.8. Market Dynamics Overview
  • 1.8.1. Market Drivers
  • 1.8.2. Market Restraints
  • 1.8.3. Market Opportunities
• 1.9. Reimbursement Scenario

2. Application

• 2.1. Application Segmentation
• 2.2. Application Summary
• 2.3. Global Acute Lymphoblastic Leukemia Therapeutics Market (by Cell Type)
  • 2.3.1. B-cell ALL
  • 2.3.2. T-cell ALL
  • 2.3.3. Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL

3. Products

• 3.1. Product Segmentation
• 3.2. Product Summary
• 3.3. Global Acute Lymphoblastic Leukemia Therapeutics Market (by Products and Services)
  • 3.3.1. Chemotherapy
  • 3.3.2. Targeted Therapy
  • 3.3.3. Radiation Therapy
  • 3.3.4. Stem Cell Transplantation

4. Regions

• 4.1. Regional Summary
• 4.2. Drivers and Restraints
• 4.3. North America
  • 4.3.1. Regional Overview
  • 4.3.2. Driving Factors for Market Growth
  • 4.3.3. Factors Challenging the Market
  • 4.3.4. Application
  • 4.3.5. Product
  • 4.3.6. U.S.
  • 4.3.7. U.S. Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.3.8. U.S. Acute Lymphoblastic Leukemia Therapeutics Market by Product
  • 4.3.9. Canada
  • 4.3.10. Canada Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.3.11. Canada Acute Lymphoblastic Leukemia Therapeutics Market by Product
• 4.4. Europe
  • 4.4.1. Regional Overview
  • 4.4.2. Driving Factors for Market Growth
  • 4.4.3. Factors Challenging the Market
  • 4.4.4. Application
  • 4.4.5. Product
  • 4.4.6. France
  • 4.4.7. France Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.4.8. France Acute Lymphoblastic Leukemia Therapeutics Market by Product
  • 4.4.9. Germany
  • 4.4.10. Germany Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.4.11. Germany Acute Lymphoblastic Leukemia Therapeutics Market by Product
  • 4.4.12. U.K.
  • 4.4.13. U.K. Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.4.14. U.K. Acute Lymphoblastic Leukemia Therapeutics Market by Product
  • 4.4.15. Rest of Europe
  • 4.4.16. Rest of Europe Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.4.17. Rest of Europe Acute Lymphoblastic Leukemia Therapeutics Market by Product
• 4.5. Asia Pacific
  • 4.5.1. Regional Overview
  • 4.5.2. Driving Factors for Market Growth
  • 4.5.3. Factors Challenging the Market
  • 4.5.4. Application
  • 4.5.5. Product
  • 4.5.6. China
  • 4.5.7. China Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.5.8. China Acute Lymphoblastic Leukemia Therapeutics Market by Product
  • 4.5.9. India
  • 4.5.10. India Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.5.11. India Acute Lymphoblastic Leukemia Therapeutics Market by Product
  • 4.5.12. Japan
  • 4.5.13. Japan Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.5.14. Japan Acute Lymphoblastic Leukemia Therapeutics Market by Product
  • 4.5.15. Rest-of-Asia-Pacific
  • 4.5.16. Rest-of-Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.5.17. Rest-of-Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market by Product
• 4.6. Rest-of-the-World
  • 4.6.1. Regional Overview
  • 4.6.2. Driving Factors for Market Growth
  • 4.6.3. Factors Challenging the Market
  • 4.6.4. Application
  • 4.6.5. Product
  • 4.6.6. The Middle East and Africa
  • 4.6.7. The Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.6.8. The Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market by Product
  • 4.6.9. Latin America
  • 4.6.10. Latin America Acute Lymphoblastic Leukemia Therapeutics Market by Application
  • 4.6.11. Latin America Acute Lymphoblastic Leukemia Therapeutics Market by Product

5. Markets - Competitive Benchmarking & Company Profiles

• 5.1. Next Frontiers…..
• 5.2. Geographic Assessment
  • 5.2.1. AbbVie Inc.
    • 5.2.1.1. Overview
    • 5.2.1.2. Top Products / Product Portfolio
    • 5.2.1.3. Top Competitors
    • 5.2.1.4. Target Customers
    • 5.2.1.5. Key Personnel
    • 5.2.1.6. Analyst View
    • 5.2.1.7. Market Share
  • 5.2.2. DAIICHI SANKYO COMPANY, LIMITED.
    • 5.2.2.1. Overview
    • 5.2.2.2. Top Products / Product Portfolio
    • 5.2.2.3. Top Competitors
    • 5.2.2.4. Target Customers
    • 5.2.2.5. Key Personnel
    • 5.2.2.6. Analyst View
    • 5.2.2.7. Market Share
  • 5.2.3. Amgen Inc.
    • 5.2.3.1. Overview
    • 5.2.3.2. Top Products / Product Portfolio
    • 5.2.3.3. Top Competitors
    • 5.2.3.4. Target Customers
    • 5.2.3.5. Key Personnel
    • 5.2.3.6. Analyst View
    • 5.2.3.7. Market Share
  • 5.2.4. Bristol-Myers Squibb Company
    • 5.2.4.1. Overview
    • 5.2.4.2. Top Products / Product Portfolio
    • 5.2.4.3. Top Competitors
    • 5.2.4.4. Target Customers
    • 5.2.4.5. Key Personnel
    • 5.2.4.6. Analyst View
    • 5.2.4.7. Market Share
  • 5.2.5. Eisai Co., Ltd.
    • 5.2.5.1. Overview
    • 5.2.5.2. Top Products / Product Portfolio
    • 5.2.5.3. Top Competitors
    • 5.2.5.4. Target Customers
    • 5.2.5.5. Key Personnel
    • 5.2.5.6. Analyst View
    • 5.2.5.7. Market Share
  • 5.2.6. Erytech Pharma Inc.
    • 5.2.6.1. Overview
    • 5.2.6.2. Top Products / Product Portfolio
    • 5.2.6.3. Top Competitors
    • 5.2.6.4. Target Customers
    • 5.2.6.5. Key Personnel
    • 5.2.6.6. Analyst View
    • 5.2.6.7. Market Share
  • 5.2.7. Fate Therapeutics
    • 5.2.7.1. Overview
    • 5.2.7.2. Top Products / Product Portfolio
    • 5.2.7.3. Top Competitors
    • 5.2.7.4. Target Customers
    • 5.2.7.5. Key Personnel
    • 5.2.7.6. Analyst View
    • 5.2.7.7. Market Share
  • 5.2.8. F. Hoffmann-La Roche Ltd
    • 5.2.8.1. Overview
    • 5.2.8.2. Top Products / Product Portfolio
    • 5.2.8.3. Top Competitors
    • 5.2.8.4. Target Customers
    • 5.2.8.5. Key Personnel
    • 5.2.8.6. Analyst View
    • 5.2.8.7. Market Share
  • 5.2.9. Genmab A/S
    • 5.2.9.1. Overview
    • 5.2.9.2. Top Products / Product Portfolio
    • 5.2.9.3. Top Competitors
    • 5.2.9.4. Target Customers
    • 5.2.9.5. Key Personnel
    • 5.2.9.6. Analyst View
    • 5.2.9.7. Market Share
  • 5.2.10. Gilead Sciences, Inc.
    • 5.2.10.1. Overview
    • 5.2.10.2. Top Products / Product Portfolio
    • 5.2.10.3. Top Competitors
    • 5.2.10.4. Target Customers
    • 5.2.10.5. Key Personnel
    • 5.2.10.6. Analyst View
    • 5.2.10.7. Market Share
  • 5.2.11. GSK plc.
    • 5.2.11.1. Overview
    • 5.2.11.2. Top Products / Product Portfolio
    • 5.2.11.3. Top Competitors
    • 5.2.11.4. Target Customers
    • 5.2.11.5. Key Personnel
    • 5.2.11.6. Analyst View
    • 5.2.11.7. Market Share
  • 5.2.12. Jazz Pharmaceuticals, Inc.
    • 5.2.12.1. Overview
    • 5.2.12.2. Top Products / Product Portfolio
    • 5.2.12.3. Top Competitors
    • 5.2.12.4. Target Customers
    • 5.2.12.5. Key Personnel
    • 5.2.12.6. Analyst View
    • 5.2.12.7. Market Share
  • 5.2.13. Juventas Cell Therapy Ltd.
    • 5.2.13.1. Overview
    • 5.2.13.2. Top Products / Product Portfolio
    • 5.2.13.3. Top Competitors
    • 5.2.13.4. Target Customers
    • 5.2.13.5. Key Personnel
    • 5.2.13.6. Analyst View
    • 5.2.13.7. Market Share
  • 5.2.14. Novartis AG
    • 5.2.14.1. Overview
    • 5.2.14.2. Top Products / Product Portfolio
    • 5.2.14.3. Top Competitors
    • 5.2.14.4. Target Customers
    • 5.2.14.5. Key Personnel
    • 5.2.14.6. Analyst View
    • 5.2.14.7. Market Share
  • 5.2.15. Pfizer Inc.
    • 5.2.15.1. Overview
    • 5.2.15.2. Top Products / Product Portfolio
    • 5.2.15.3. Top Competitors
    • 5.2.15.4. Target Customers
    • 5.2.15.5. Key Personnel
    • 5.2.15.6. Analyst View
    • 5.2.15.7. Market Share
  • 5.2.16. Regeneron Pharmaceuticals Inc.
    • 5.2.16.1. Overview
    • 5.2.16.2. Top Products / Product Portfolio
    • 5.2.16.3. Top Competitors
    • 5.2.16.4. Target Customers
    • 5.2.16.5. Key Personnel
    • 5.2.16.6. Analyst View
    • 5.2.16.7. Market Share
  • 5.2.17. Sanofi
    • 5.2.17.1. Overview
    • 5.2.17.2. Top Products / Product Portfolio
    • 5.2.17.3. Top Competitors
    • 5.2.17.4. Target Customers
    • 5.2.17.5. Key Personnel
    • 5.2.17.6. Analyst View
    • 5.2.17.7. Market Share
  • 5.2.18. Seagen Inc.
    • 5.2.18.1. Overview
    • 5.2.18.2. Top Products / Product Portfolio
    • 5.2.18.3. Top Competitors
    • 5.2.18.4. Target Customers
    • 5.2.18.5. Key Personnel
    • 5.2.18.6. Analyst View
    • 5.2.18.7. Market Share
  • 5.2.19. Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
    • 5.2.19.1. Overview
    • 5.2.19.2. Top Products / Product Portfolio
    • 5.2.19.3. Top Competitors
    • 5.2.19.4. Target Customers
    • 5.2.19.5. Key Personnel
    • 5.2.19.6. Analyst View
    • 5.2.19.7. Market Share

6. Research Methodology

• 6.1. Data Sources
  • 6.1.1. Primary Data Sources
  • 6.1.2. Secondary Data Sources
  • 6.1.3. Data Triangulation
• 6.2. Market Estimation and Forecast

관련자료